Filing Details

Accession Number:
0001104659-21-113493
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-09-07 17:30:39
Reporting Period:
2021-09-02
Accepted Time:
2021-09-07 17:30:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1722964 Y-Mabs Therapeutics Inc. YMAB Pharmaceutical Preparations (2834) 474619612
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1753224 Thomas Gad C/O Y-Mabs Therapeutics, Inc.
230 Park Avenue, Suite 3350
New York NY 10169
See Remarks Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-09-02 50,000 $33.18 1,504,927 No 4 S Indirect By GAD Enterprises LLC
Common Stock Acquisiton 2021-09-07 50,000 $2.00 50,000 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By GAD Enterprises LLC
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2021-09-07 50,000 $0.00 50,000 $2.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
219,000 2025-06-10 No 4 M Direct
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $33.10 to $33.74. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
  3. The stock option vested and became exercisable as to 25% of the shares subject to the option on June 10, 2016, and thereafter vested as to 1/48th of the shares in equal monthly installments, until such time as the option was 100% vested on June 10, 2019.